402 related articles for article (PubMed ID: 16240238)
1. Curcumin therapy in inflammatory bowel disease: a pilot study.
Holt PR; Katz S; Kirshoff R
Dig Dis Sci; 2005 Nov; 50(11):2191-3. PubMed ID: 16240238
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
3. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
[TBL] [Abstract][Full Text] [Related]
5. [Changing treatment of inflammatory bowel diseases].
Karvonen AL; Matikainen M; Turunen U
Duodecim; 1994; 110(20):1945-54. PubMed ID: 7555809
[No Abstract] [Full Text] [Related]
6. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
[TBL] [Abstract][Full Text] [Related]
7. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study.
Singla V; Pratap Mouli V; Garg SK; Rai T; Choudhury BN; Verma P; Deb R; Tiwari V; Rohatgi S; Dhingra R; Kedia S; Sharma PK; Makharia G; Ahuja V
J Crohns Colitis; 2014 Mar; 8(3):208-14. PubMed ID: 24011514
[TBL] [Abstract][Full Text] [Related]
8. A preliminary study of growth hormone therapy for Crohn's disease.
Slonim AE; Bulone L; Damore MB; Goldberg T; Wingertzahn MA; McKinley MJ
N Engl J Med; 2000 Jun; 342(22):1633-7. PubMed ID: 10833209
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
10. Low-dose naltrexone therapy improves active Crohn's disease.
Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
[TBL] [Abstract][Full Text] [Related]
11. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Cohen A; Bitton A; Baker J; Dubé R; Landau SB; Vandervoort MK; Parikh A
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1370-7. PubMed ID: 18829392
[TBL] [Abstract][Full Text] [Related]
12. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
Domènech E; Hinojosa J; Esteve-Comas M; Gomollón F; Herrera JM; Bastida G; Obrador A; Ruiz R; Saro C; Gassull MA;
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1347-52. PubMed ID: 15606397
[TBL] [Abstract][Full Text] [Related]
13. [First line therapy of inflammatory bowel disease].
Poullenot F; Laharie D
Rev Prat; 2014 Nov; 64(9):1242-8. PubMed ID: 25638863
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
[TBL] [Abstract][Full Text] [Related]
15. Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
Yamamoto K; Chiba T; Matsumoto T
World J Gastroenterol; 2015 Sep; 21(35):10208-14. PubMed ID: 26401086
[TBL] [Abstract][Full Text] [Related]
16. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
Panés J; López-Sanromán A; Bermejo F; García-Sánchez V; Esteve M; Torres Y; Domènech E; Piqueras M; Gomez-García M; Gutiérrez A; Taxonera C; Sans M;
Gastroenterology; 2013 Oct; 145(4):766-74.e1. PubMed ID: 23770132
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
18. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial.
Krebs S; Omer TN; Omer B
Phytomedicine; 2010 Apr; 17(5):305-9. PubMed ID: 19962291
[TBL] [Abstract][Full Text] [Related]
19. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis.
Fukunaga K; Ohda Y; Hida N; Iimuro M; Yokoyama Y; Kamikozuru K; Nagase K; Nakamura S; Miwa H; Matsumoto T
J Gastroenterol Hepatol; 2012 Dec; 27(12):1808-15. PubMed ID: 22775479
[TBL] [Abstract][Full Text] [Related]
20. Hand-held fractional exhaled nitric oxide measurements as a non-invasive indicator of systemic inflammation in Crohn's disease.
Quenon L; Hindryckx P; De Vos M; De Looze D; Joos G; Brusselle G; Peeters H
J Crohns Colitis; 2013 Sep; 7(8):644-8. PubMed ID: 23083698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
